ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones Portfolio News / By Karina Tin January 11, 2021 ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones Read More »
eFFECTOR Appoints Mike Byrnes as Chief Financial Officer Portfolio News / By Karina Tin January 7, 2021 eFFECTOR Appoints Mike Byrnes as Chief Financial Officer Read More »
Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer Portfolio News / By Karina Tin January 7, 2021 Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer Read More »
Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies Portfolio News / By Karina Tin January 7, 2021 Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies Read More »
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock PDF Version Portfolio News / By Karina Tin January 5, 2021 NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock PDF Version Read More »
A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers Portfolio News / By Karina Tin December 23, 2020 A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers Read More »
ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101 Portfolio News / By Karina Tin December 21, 2020 ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101 Read More »
NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors Portfolio News / By Karina Tin December 9, 2020 NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors Read More »
Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing Portfolio News / By Karina Tin December 8, 2020 Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing Read More »
Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition Portfolio News / By Karina Tin December 7, 2020 Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition Read More »
